Hemophilia A (F8) Gene Mutation Analysis
Hemophilia A is an X-linked recessive bleeding disorder associated with mutation in the Factor VIII gene located on the long arm of the X chromosome within the Xq28 region. A mutation results in a decreased amount of FVIII or an abnormally functioning protein. Affected individuals present with variable degrees of excessive bleeding, either spontaneously or from minor injury. Common disease manifestations include: hemarthrosis, hematoma, gastrointestinal bleeding, and genitourinary bleeding.
Factor VIII is part of the intrinsic coagulation pathway. Most patients are males since females have two copies of the X chromosome and can make enough Factor VIII with one normal copy, whereas males have only one X chromosome. About 1 in 4,500 males worldwide are born with this disorder. Another form of hemophilia is the acquired form in which patients develop antibodies directed against their own Factor VIII (autoantibodies). More than 200 mutations with diverse effects have been described for the factor VIII gene. Of patients with severe hemophilia about half have an F8 gene intron 22-A inversion and another 1 to 3% have an F8 intron 1 inversion. Most of the remaining patients with severe hemophilia A have gross gene alterations including significant deletions or insertions, nonsense or missense mutations, splice junction or frameshift mutations.
In patients with mild to moderate hemophilia A, missense mutations often occur within the exon that codes for the three A domains and two C domains. Some patients at first appear to have de novo mutations, but in these the mother is determined by genetic analysis to be the carrier in almost all. Sequence analysis followed by deletion/duplication analysis is often used to confirm gene defects in males. In females sequence analysis may miss some defects and deletion/duplication analysis can identify relevant rearrangements and deletions. Disease severity is dependent on circulating values of F VIII and is classified as follows:
Expected F VIII levels for normal individuals: 50 - 150%
F VIII values in individuals presenting with hemophilia:
>5% (>0.05 to <0.40 IU/mL — mild hemophilia
1-5% (0.01 – 0.05 IU/mL) — moderate hemophilia
<1% (<0.01 IU/mL) — severe hemophilia
F VIII replacement therapy is the preferred treatment regimen for patients with hemophilia A. If an individual develops an alloantibody (inhibitor) against exogenous Factor VIII, efficacy of treatment is diminished.
- Determination of specific F8 genetic mutation in individuals affected with hemophilia A
- Determination of carrier status for women with a family history of hemophilia A
- Early determination of genetic status for high risk males
- Prenatal testing for carrier status
Predictive of severe hemophilia A disease state in males and carrier status for females:
- Detection of one copy of the F8 intron 22A or intron 1 inversion
- Identification of a large F8 deletion or duplication
Predictive of variable hemophilia A severity in males and carrier status in females:
- detection of a deleterious mutation in the F8 gene
Negative results do not exclude hemophilia A due to the possibility of undetectable mutations in the F8 gene.
Negative for mutations analyzed (Mutation not detected)
High resolution melt curve analysis (HRM), multiplex ligation–dependent probe amplification (MLPA), microarray technology, mutation specific gap polymerase chain reaction (PCR), reverse transcription (RT–PCR from mRNA, DNA sequencing
Whole blood collected in EDTA (lavender top tube) or ACD (blue top tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
Complete blood count (CBC) with platelet count, coagulation studies, factor VIII activity assay, and prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet function analysis, genetic counseling.
5-10 days.
- N Engl J Med. 2013 Jan 17;368(3):231-9. [PMID: 23323899]
- Ther Adv Hematol. 2013 Feb;4(1):59-72. [PMID: 23610614]
- Pagon RA, Bird TD et al. “Hemophilia A.” [PMID: 20301578]
- Semin Thromb Hemost. 2012 Oct;38(7):735-41. [PMID: 22941793]
- Am J Obstet Gynecol. 1996 Sep;175(3 Pt 2):778-83. [PMID: 8828561]